A multi-omic dissection of super-enhancer driven oncogenic gene expression programs in ovarian cancer

被引:0
|
作者
Michael R. Kelly
Kamila Wisniewska
Matthew J. Regner
Michael W. Lewis
Andrea A. Perreault
Eric S. Davis
Douglas H. Phanstiel
Joel S. Parker
Hector L. Franco
机构
[1] University of North Carolina at Chapel Hill,Lineberger Comprehensive Cancer Center
[2] University of North Carolina at Chapel Hill,Bioinformatics and Computational Biology Graduate Program
[3] University of North Carolina at Chapel Hill,Thurston Arthritis Research Center
[4] University of North Carolina at Chapel Hill,Department of Cell Biology & Physiology
[5] University of North Carolina at Chapel Hill,Department of Genetics, School of Medicine
来源
Nature Communications | / 13卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The human genome contains regulatory elements, such as enhancers, that are often rewired by cancer cells for the activation of genes that promote tumorigenesis and resistance to therapy. This is especially true for cancers that have little or no known driver mutations within protein coding genes, such as ovarian cancer. Herein, we utilize an integrated set of genomic and epigenomic datasets to identify clinically relevant super-enhancers that are preferentially amplified in ovarian cancer patients. We systematically probe the top 86 super-enhancers, using CRISPR-interference and CRISPR-deletion assays coupled to RNA-sequencing, to nominate two salient super-enhancers that drive proliferation and migration of cancer cells. Utilizing Hi-C, we construct chromatin interaction maps that enable the annotation of direct target genes for these super-enhancers and confirm their activity specifically within the cancer cell compartment of human tumors using single-cell genomics data. Together, our multi-omic approach examines a number of fundamental questions about how regulatory information encoded into super-enhancers drives gene expression networks that underlie the biology of ovarian cancer.
引用
收藏
相关论文
共 50 条
  • [21] Multi-omic dissection of immunotherapy response groups in non-small cell lung cancer (NSCLC)
    Kulasinghe, Arutha
    Monkman, James
    Kim, Honesty
    Mayer, Aaron
    Mehdi, Ahmed
    Matigian, Nicholas
    Cumberbatch, Marie
    Bhagat, Milan
    Ladwa, Rahul
    Mueller, Scott
    Adams, Mark
    O'Byrne, Ken
    CANCER RESEARCH, 2022, 82 (12)
  • [22] Multi-omic and spatial dissection of immunotherapy response groups in non-small cell lung cancer
    Monkman, James
    Kim, Honesty
    Mayer, Aaron
    Mehdi, Ahmed
    Matigian, Nicholas
    Cumberbatch, Marie
    Bhagat, Milan
    Ladwa, Rahul
    Mueller, Scott N.
    Adams, Mark N.
    O'Byrne, Ken
    Kulasinghe, Arutha
    IMMUNOLOGY, 2023, 169 (04) : 487 - 502
  • [23] Integrative analysis to identify oncogenic gene expression changes associated with copy number variations of enhancer in ovarian cancer
    Li, Xiaoyan
    Liu, Yining
    Lu, Jiachun
    Zhao, Min
    ONCOTARGET, 2017, 8 (53) : 91558 - 91567
  • [24] LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer
    Li, Muqing
    Liu, Mingyu
    Han, Wanting
    Wang, Zifeng
    Han, Dong
    Patalano, Susan
    Macoska, Jill A.
    Balk, Steven P.
    He, Housheng Hansen
    Corey, Eva
    Gao, Shuai
    Cai, Changmeng
    CANCER RESEARCH, 2023, 83 (10) : 1684 - 1698
  • [25] BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer
    Yokoyama, Yuhki
    Zhu, Hengrui
    Lee, Jeong Heon
    Kossenkov, Andrew V.
    Wu, Sherry Y.
    Wickramasinghe, Jayamanna M.
    Yin, Xiangfan
    Palozola, Katherine C.
    Gardini, Alessandro
    Showe, Louise C.
    Zaret, Kenneth S.
    Liu, Qin
    Speicher, David
    Conejo-Garcia, Jose R.
    Bradner, James E.
    Zhang, Zhiguo
    Sood, Anil K.
    Ordog, Tamas
    Bitler, Benjamin G.
    Zhang, Rugang
    CANCER RESEARCH, 2016, 76 (21) : 6320 - 6330
  • [26] Multi-omic integration of DNA methylation and gene expression data reveals molecular vulnerabilities in glioblastoma
    Santamarina-Ojeda, Pablo
    Tejedor, Juan Ramon
    Perez, Raul F.
    Lopez, Virginia
    Roberti, Annalisa
    Mangas, Cristina
    Fernandez, Agustin F.
    Fraga, Mario F. F.
    MOLECULAR ONCOLOGY, 2023, 17 (09) : 1726 - 1743
  • [27] BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-enhancer in Ovarian Cancer
    Yokoyama, Yuhki
    Takeda, Takashi
    Kitagawa, Kumi
    Mori, Seiji
    Mizushima, Tsunekazu
    Mori, Masaki
    Matsuura, Nariaki
    Yamamoto, Hirofumi
    CANCER SCIENCE, 2018, 109 : 1300 - 1300
  • [28] Multi-omic characterization and predictive features of advanced ovarian cancer patients in a large phase III cohort
    Ramathal, Cyril
    Masica, David
    Ansell, Peter
    Riley-Gillis, Bridget
    Degner, Jacob
    Bui, Thanh
    Narayanan, Priya
    Samayoa, Josue
    Huang, Xin
    Coleman, Robert F.
    Waring, Jeffrey F.
    CANCER RESEARCH, 2023, 83 (07)
  • [29] Super-Enhancer Redistribution as a Mechanism of Broad Gene Dysregulation in Repeatedly Drug-Treated Cancer Cells
    Ma, Qi
    Yang, Feng
    Mackintosh, Carlos
    Jayani, Ranveer Singh
    Oh, Soohwan
    Jin, Chunyu
    Nair, Sreejith Janardhanan
    Merkurjev, Daria
    Ma, Wubin
    Allen, Stephanie
    Wang, Dong
    Almenar-Queralt, Angels
    Garcia-Bassets, Ivan
    CELL REPORTS, 2020, 31 (03):
  • [30] Mediator kinase module proteins, genetic alterations and expression of super-enhancer regulated genes in colorectal cancer
    Voutsadakis, Ioannis
    PHARMACOLOGICAL REPORTS, 2024, 76 (03) : 535 - 556